The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...

If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...